Thomas Sciascia, Chief Scientific Officer at Trevi Therapeutics, Inc. (TRVI), sold 106,736 shares at $2.55 ($272K) on 2024-05-29, disclosed to the SEC on 2024-05-31.
Open-market sale of $272k TRVI by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.55 | 53,368 | $136K | 50.0% |
| 2 | $2.55 | 53,368 | $136K | 50.0% |
| Total | $2.55 avg | 106,736 | $272K | 100% |
| Filing → |
| TRVI | SELL | 2024-08-16 | $139K | — | Filing → |